About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
HEM in 90
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Investor
Investor Presentations
A Three Minute Summary
Analysts
Public Filings
AGM Materials
MENU ≡
About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
HEM in 90
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Investor
Investor Presentations
A Three Minute Summary
Analysts
Public Filings
AGM Materials
Contact
Thomas A. Smeenk, BA
President & CEO, Co-Founder
Hemostemix Inc. TSXV:HEM
905-580-4170
tsmeenk@hemostemix.com
